Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 25:10:103-6.
doi: 10.4137/BCBCR.S33163. eCollection 2016.

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer

Angela Pennisi  1 , Thomas Kieber-Emmons  1 , Issam Makhoul  1 , Laura Hutchins  1
Affiliations
Review

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer

Angela Pennisi et al. Breast Cancer (Auckl). .

Abstract

Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, the definition of pCR has lacked uniformity, and the prognostic impact of achievement of pCR on survival in different breast cancer subtypes is uncertain. In this review, we present the controversies associated with the use of pCR as an end point in neoadjuvant trials.

Keywords: breast cancer; neoadjuvant; pathological complete response.

PubMed Disclaimer

References

    1. Mieog JS, van de Velde CJ. Neoadjuvant chemotherapy for early breast cancer. Expert Opinion on Pharmacotherapy. 2009;10(9):1423–1434. - PubMed
    1. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(5):778–785. - PubMed
    1. Center for Drug Evaluation and Research. Food and Drug Administration, US Department of Health and Human Services . Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Silver Spring, MD: Food and Drug Administration; Available online: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformati....
    1. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2006;24(13):2019–2027. - PubMed
    1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001;19(22):4224–4237. - PubMed

LinkOut - more resources